Saniona AB (publ) (STO:SANION)

Market Cap	1.78B +52.1%
Revenue (ttm)	429.29M +26.8%
Net Income	219.56M +1.2%
EPS	1.60 -16.4%
Shares Out	138.03M
PE Ratio	8.08
Forward PE	30.78
Dividend	n/a
Ex-Dividend Date	n/a

Volume	256,733
Open	13.36
Previous Close	13.05
Day's Range	12.78 - 13.42
52-Week Range	8.03 - 28.30
Beta	1.21
Analysts	n/a
Price Target	20.00 (+54.92%)
Earnings Date	May 26, 2026

About Saniona AB

Saniona AB (publ), a clinical-stage biopharmaceutical company, focuses on discovering, developing, and delivering innovative treatments for neurological and psychiatric disorders in Ireland, the United States, Germany, Denmark, and the United Kingdom. It also develops medicines modulating ion channels. The company’s product includes Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical trial to treat people with obesity; and Tesomet, an oral investigational therapy that has completed Phase 2 clinical trial for the trea...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 43
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: SANION

Financial Performance

In 2025, Saniona AB's revenue was 434.40 million, an increase of 29.80% compared to the previous year's 334.67 million. Earnings were 284.67 million, an increase of 50.85%.